

CytoTools AG presented results of the Indian phase III trial with great success at one of Asia's largest diabetes conferences

- Experts at the Indian diabetes conference show very great interest in the active substance
- Talks in progress on production and market launch
- Application made to the WHO for Wannoxyme to be the scientific name of DermaPro®

Darmstadt, 25th September 2013 – Centaur Pharmaceuticals, a partner of the technology holding CytoTools AG, which is active in the pharmaceutical and medical products fields, presented the results of the Indian phase III trial to a wide expert audience made up of more than 400 diabetes specialists at the diabetes conference “DFSICON 2013” in Jaipur, India. As well as the presentation by Dr. Sudhir K Jain, one of the participating practitioners in the trial, the excellent results of the trial were explained at the Centaur stand and at meetings with leading specialists. This breakthrough in the treatment of diabetic foot was discussed in detail with more than 85 medical professionals eager to learn about the active substance. Furthermore, in special meetings with all the important opinion leaders from the chronic wound treatment field, individual results and special aspects were reviewed.

Here, for the first time, the new scientific name for DermaPro® was presented. An application has been submitted to the WHO and, when the approval is given, the new molecule will be known by the chemical name Wannoxyme. CytoTools has the right of proposal for the chemical name of the compound because this new substance represents a separate class of molecules. This fact underlines yet again the pioneering achievement of the company in recent years in the research and development of this active substance.

Dr. Dirk Kaiser, Managing Director of CytoTools AG, summarized the impressions of the Indian colleagues: „According to our partners, the physicians at the conference were absolutely enthralled by the new therapy possibilities which have been created by our active substance. Not only the absolute number of over 91% of patients responding excellently, but in particular the very fast effectiveness - with an average of slightly less than 6 weeks for complete wound closure after starting treatment - met with a highly positive echo” , Dr. Kaiser explained.

PRESS RELEASE



The first class safety profile is also classified as a decisive advantage. Until today, throughout all studies, there has not been a negative incident. Another key market advantage lies in the fact that the active substance does not have to be cooled – an important argument particularly for the Indian market.

Dr. Mukund Zarpkar, the leading physician in the Indian study, summarized: „With Wannoxyme, we as physicians, for the first time, have a patented, extremely effective medium available with which we can treat diabetic foot effectively. Against this background, we look forward with great expectations to the results of the upcoming trials for further indications, then we see a much greater potential in the active substance molecule Wannoxyme.“ The registration documents will be submitted to the Indian authorities in the coming weeks. Dr. Zarpkar added: „We are very proud that here, for the first time, an innovative, worldwide patented active substance, which was developed in Germany, will be available first in India. Considering the very large number of patients affected in India, we are convinced that this active substance will develop its own market in the field of wound healing.“

Furthermore, the enormous scientific interest, particularly in the Indian market, is evidence for the immense potential of DermaPro® in future. Currently, talks are being held in India between the management boards of CytoTools AG and Centaur Pharmaceuticals to prepare and coordinate the market launch in the coming year. The talks will specify when the production of the first large batches of DermaPro® for the Indian market can begin and when the first orders can be made.

This release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

CytoTools AG, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: around 58% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

PRESS RELEASE



CytoTools

Contact:

CytoTools AG

Dr. Mark Andre Freyberg

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: freyberg@cytotools.de

Press contact:

cometis AG

Ulrich Wiehle

Unter den Eichen 7

D-65195 Wiesbaden

Tel.: +49-611-205855-11

Fax: +49-611-205855-66

E-Mail: wiehle@cometis.de